Long-term consequences of adolescent cannabinoid exposure in adult psychopathology

Frontiers in Neuroscience

Volumn 8, Issue OCT, 2014, Pages

  Renard, Justine ^a,b   Krebs, Marie Odile ^a,b   Le Pen, Gwenaëlle ^a,b   Jay, Thérèse M ^a,b  

^a CENTRE DE PSYCHIATRIE ET NEUROSCIENCES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Adolescence; Behavior; Cannabinoids; Long term consequences; Psychosis

Indexed keywords

CANNABINOID RECEPTOR; CANNABIS; ENDOCANNABINOID; NEU DIFFERENTIATION FACTOR;

ADOLESCENT; ADOLESCENT BEHAVIOR; ADULT; ANXIETY DISORDER; ARTICLE; BRAIN MATURATION; CANNABIS USE; COGNITION; COGNITIVE DEFECT; DEPRESSION; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; LONG TERM EXPOSURE; MENTAL DISEASE; NERVE CELL PLASTICITY; NEUROIMAGING; NONHUMAN; PYRAMIDAL NERVE CELL; SCHIZOPHRENIA; SENSORY GATING;

EID: 84949117809     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2014.00361     Document Type: Article

References (140)

1. Abush H, Akirav I (2012) Short- and long-term cognitive effects of chronic cannabinoids administration in late-adolescence rats. PLoS One 7:e31731.
2. Ahmad T, Lauzon NM, de J, X, Laviolette SR (2013) Cannabinoid transmission in the prelimbic cortex bidirectionally controls opiate reward and aversion signaling through dissociable kappa versus mu-opiate receptor dependent mechanisms. J Neurosci 33:15642-15651.
3. Amen DG, Waugh M (1998) High resolution brain SPECT imaging of marijuana smokers with AD/HD. J Psychoactive Drugs 30:209-214.
4. Andersen SL (2003) Trajectories of brain development: point of vulnerability or window of opportunity? Neurosci Biobehav Rev 27:3-18
5. Andreasson S, Allebeck P, Engstrom A, Rydberg U (1987) Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 2:1483-1486.
6. Arendt M, Mortensen PB, Rosenberg R, Pedersen CB, Waltoft BL (2008) Familial predisposition for psychiatric disorder: comparison of subjects treated for cannabis-induced psychosis and schizophrenia. Arch Gen Psychiatry 65:1269-1274.
7. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE (2002) Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 325:1212-1213.
8. Arseneault L, Cannon M, Witton J, Murray RM (2004) Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 184:110-117.
9. Ashtari M, Avants B, Cyckowski L, Cervellione KL, Roofeh D, Cook P, Gee J, Sevy S, Kumra S (2011) Medial temporal structures and memory functions in adolescents with heavy cannabis use. J Psychiatr Res 45:1055-1066.
10. Bambico FR, Nguyen NT, Katz N, Gobbi G (2010) Chronic exposure to cannabinoids during adolescence but not during adulthood impairs emotional behaviour and monoaminergic neurotransmission. Neurobiol Dis 37:641-655.
11. Bartzokis G, Beckson M, Lu PH, Nuechterlein KH, Edwards N, Mintz J (2001) Age-related changes in frontal and temporal lobe volumes in men: a magnetic resonance imaging study. Arch Gen Psychiatry 58:461-465.
12. Bayer TA, Falkai P, Maier W (1999) Genetic and non-genetic vulnerability factors in schizophrenia: the basis of the "two hit hypothesis". J Psychiatr Res 33:543-548.
13. Becker B, Wagner D, Gouzoulis-Mayfrank E, Spuentrup E, Daumann J (2010a) Altered parahippocampal functioning in cannabis users is related to the frequency of use. Psychopharmacology (Berl) 209:361-374.
14. Becker B, Wagner D, Gouzoulis-Mayfrank E, Spuentrup E, Daumann J (2010b) The impact of early-onset cannabis use on functional brain correlates of working memory. Prog Neuropsychopharmacol Biol Psychiatry 34:837-845.
15. Behan AT, Hryniewiecka M, O'Tuathaigh CM, Kinsella A, Cannon M, Karayiorgou M, Gogos JA, Waddington JL, Cotter DR (2012) Chronic adolescent exposure to delta-9-tetrahydrocannabinol in COMT mutant mice: impact on indices of dopaminergic, endocannabinoid and GABAergic pathways. Neuropsychopharmacology 37:1773-1783.
16. Berghuis P, Dobszay MB, Wang X, Spano S, Ledda F, Sousa KM, Schulte G, Ernfors P, Mackie K, Paratcha G, Hurd YL, Harkany T (2005) Endocannabinoids regulate interneuron migration and morphogenesis by transactivating the TrkB receptor. Proc Natl Acad Sci U S A 102:19115-19120.
17. Berghuis P, Rajnicek AM, Morozov YM, Ross RA, Mulder J, Urban GM, Monory K, Marsicano G, Matteoli M, Canty A, Irving AJ, Katona I, Yanagawa Y, Rakic P, Lutz B, Mackie K, Harkany T (2007) Hardwiring the brain: endocannabinoids shape neuronal connectivity. Science 316:1212-1216.
18. Biscaia M, Marin S, Fernandez B, Marco EM, Rubio M, Guaza C, Ambrosio E, Viveros MP (2003) Chronic treatment with CP 55,940 during the peri-adolescent period differentially affects the behavioural responses of male and female rats in adulthood. Psychopharmacology (Berl) 170:301-308.
19. Bortolato M, Bini V, Frau R, Devoto P, Pardu A, Fan Y, Solbrig MV (2014) Juvenile cannabinoid treatment induces frontostriatal gliogenesis in Lewis rats. Eur Neuropsychopharmacol 24:974-985.
20. Boucher AA, Arnold JC, Duffy L, Schofield PR, Micheau J, Karl T (2007a) Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Delta9-tetrahydrocannabinol. Psychopharmacology (Berl) 192:325-336.
21. Boucher AA, Hunt GE, Karl T, Micheau J, McGregor IS, Arnold JC (2007b) Heterozygous neuregulin 1 mice display greater baseline and Delta(9)-tetrahydrocannabinol-induced c-Fos expression. Neuroscience 149:861-870.
22. Boucher AA, Hunt GE, Micheau J, Huang X, McGregor IS, Karl T, Arnold JC (2011) The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids. Int J Neuropsychopharmacol 14:631-643.
23. Braff DL, Geyer MA, Swerdlow NR (2001) Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 156:234-258.
24. Casey BJ, Giedd JN, Thomas KM (2000) Structural and functional brain development and its relation to cognitive development. Biol Psychol 54:241-257.
25. Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, Taylor A, Arseneault L, Williams B, Braithwaite A, Poulton R, Craig IW (2005) Moderation of the effect of adolescentonset cannabis use on adult psychosis by a functional polymorphism in the catechol-Omethyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 57:1117-1127.
26. Cha YM, Jones KH, Kuhn CM, Wilson WA, Swartzwelder HS (2007) Sex differences in the effects of delta9-tetrahydrocannabinol on spatial learning in adolescent and adult rats. Behav Pharmacol 18:563-569.
27. Chabrol H, Chauchard E, Girabet J (2008) Cannabis use and suicidal behaviours in high-school students. Addict Behav 33:152-155.
28. Chechik G, Meilijson I, Ruppin E (1999) Neuronal regulation: A mechanism for synaptic pruning during brain maturation. Neural Comput 11:2061-2080.
29. Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, Kolachana BS, Hyde TM, Herman MM, Apud J, Egan MF, Kleinman JE, Weinberger DR (2004) Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 75:807-821.
30. Churchwell JC, Lopez-Larson M, Yurgelun-Todd DA (2010) Altered frontal cortical volume and decision making in adolescent cannabis users. Front Psychol 1:225.
31. Dahl RE (2004) Adolescent development and the regulation of behavior and emotion: introduction to part VIII. Ann N Y Acad Sci 1021:294-295.
32. Dalton VS, Zavitsanou K (2010) Cannabinoid effects on CB1 receptor density in the adolescent brain: an autoradiographic study using the synthetic cannabinoid HU210. Synapse 64:845-854.
33. Dean B, Sundram S, Bradbury R, Scarr E, Copolov D (2001) Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103:9-15.
34. Decoster J, van OJ, Kenis G, Henquet C, Peuskens J, De HM, van WR (2011) Age at onset of psychotic disorder: cannabis, BDNF Val66Met, and sex-specific models of gene-environment interaction. Am J Med Genet B Neuropsychiatr Genet 156B:363-369.
35. Degenhardt L, Hall W (2002) Cannabis and psychosis. Curr Psychiatry Rep 4:191-196.
36. Degenhardt L, Hall W, Lynskey M (2003) Exploring the association between cannabis use and depression. Addiction 98:1493-1504.
37. Degenhardt L, Tennant C, Gilmour S, Schofield D, Nash L, Hall W, McKay D (2007) The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study. Psychol Med 37:927-934.
38. Degenhardt L, Coffey C, Romaniuk H, Swift W, Carlin JB, Hall WD, Patton GC (2013) The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood. Addiction 108:124-133.
39. Dixon L, Haas G, Weiden P, Sweeney J, Frances A (1990) Acute effects of drug abuse in schizophrenic patients: clinical observations and patients' self-reports. Schizophr Bull 16:69-79.
40. Dougherty DM, Mathias CW, Dawes MA, Furr RM, Charles NE, Liguori A, Shannon EE, Acheson A (2013) Impulsivity, attention, memory, and decision-making among adolescent marijuana users. Psychopharmacology (Berl) 226:307-319.
41. Eggan SM, Mizoguchi Y, Stoyak SR, Lewis DA (2010) Development of cannabinoid 1 receptor protein and messenger RNA in monkey dorsolateral prefrontal cortex. Cereb Cortex 20:1164-1174.
42. Ehrenreich H, Rinn T, Kunert HJ, Moeller MR, Poser W, Schilling L, Gigerenzer G, Hoehe MR (1999) Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology (Berl) 142:295-301.
43. Ellgren M, Artmann A, Tkalych O, Gupta A, Hansen HS, Hansen SH, Devi LA, Hurd YL (2008) Dynamic changes of the endogenous cannabinoid and opioid mesocorticolimbic systems during adolescence: THC effects. Eur Neuropsychopharmacol 18:826-834.
44. Ferdinand RF, Sondeijker F, van der Ende J, Selten JP, Huizink A, Verhulst FC (2005) Cannabis use predicts future psychotic symptoms, and vice versa. Addiction 100:612-618.
45. Fergusson DM, Horwood LJ, Swain-Campbell NR (2003) Cannabis dependence and psychotic symptoms in young people. Psychol Med 33:15-21.
46. Fontes MA, Bolla KI, Cunha PJ, Almeida PP, Jungerman F, Laranjeira RR, Bressan RA, Lacerda AL (2011) Cannabis use before age 15 and subsequent executive functioning. Br J Psychiatry 198:442-447.
47. Giedd JN, Blumenthal J, Jeffries NO, Castellanos FX, Liu H, Zijdenbos A, Paus T, Evans AC, Rapoport JL (1999) Brain development during childhood and adolescence: a longitudinal MRI study. Nat Neurosci 2:861-863.
48. Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J, Klosterkotter J, Piomelli D (2004) Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29:2108-2114.
49. Goldberger C, Dervaux A, Gourion D, Bourdel MC, Loo H, Laqueille X, Krebs MO (2010) Variable individual sensitivity to cannabis in patients with schizophrenia. Int J Neuropsychopharmacol 13:1145-1154.
50. Grant BF, Pickering R (1998) The relationship between cannabis use and DSM-IV cannabis abuse and dependence: results from the National Longitudinal Alcohol Epidemiologic Survey. J Subst Abuse 10:255-264.
51. Green BE, Ritter C (2000) Marijuana use and depression. J Health Soc Behav 41:40-49.
52. Gruber SA, Dahlgren MK, Sagar KA, Gonenc A, Killgore WD (2012) Age of onset of marijuana use impacts inhibitory processing. Neurosci Lett 511:89-94.
53. Hall W, Degenhardt L (2000) Cannabis use and psychosis: a review of clinical and epidemiological evidence. Aust N Z J Psychiatry 34:26-34.
54. Hall W, Degenhardt L (2014) The adverse health effects of chronic cannabis use. Drug Test Anal 6:39-45.
55. Harkany T, Guzman M, Galve-Roperh I, Berghuis P, Devi LA, Mackie K (2007) The emerging functions of endocannabinoid signaling during CNS development. Trends Pharmacol Sci 28:83-92.
56. Harkany T, Keimpema E, Barabas K, Mulder J (2008) Endocannabinoid functions controlling neuronal specification during brain development. Mol Cell Endocrinol 286:S84-S90.
57. Hayatbakhsh MR, Najman JM, Jamrozik K, Mamun AA, Alati R, Bor W (2007) Cannabis and anxiety and depression in young adults: a large prospective study. J Am Acad Child Adolesc Psychiatry 46:408-417.
58. Heng L, Beverley JA, Steiner H, Tseng KY (2011) Differential developmental trajectories for CB1 cannabinoid receptor expression in limbic/associative and sensorimotor cortical areas. Synapse 65:278-286.
59. Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU, van OJ (2005) Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 330:11.
60. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, De Costa BR, Rice KC (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 87:1932-1936.
61. Higuera-Matas A, Botreau F, Miguens M, Del ON, Borcel E, Perez-Alvarez L, Garcia-Lecumberri C, Ambrosio E (2009) Chronic periadolescent cannabinoid treatment enhances adult hippocampal PSA-NCAM expression in male Wistar rats but only has marginal effects on anxiety, learning and memory. Pharmacol Biochem Behav 93:482-490.
62. Ho BC, Wassink TH, Ziebell S, Andreasen NC (2011) Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia. Schizophr Res 128:66-75.
63. Hsieh MH, Swerdlow NR, Braff DL (2006) Effects of background and prepulse characteristics on prepulse inhibition and facilitation: implications for neuropsychiatric research. Biol Psychiatry 59:555-559.
64. Huestegge L, Radach R, Kunert HJ, Heller D (2002) Visual search in long-term cannabis users with early age of onset. Prog Brain Res 140:377-394.
65. Jacobus J, Goldenberg D, Wierenga CE, Tolentino NJ, Liu TT, Tapert SF (2012) Altered cerebral blood flow and neurocognitive correlates in adolescent cannabis users. Psychopharmacology (Berl) 222:675-684.
66. Jager G, Block RI, Luijten M, Ramsey NF (2010) Cannabis use and memory brain function in adolescent boys: a cross-sectional multicenter functional magnetic resonance imaging study. J Am Acad Child Adolesc Psychiatry 49:561-72, 572.
67. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M (2009) Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89:309-380.
68. Katona I (2009) Endocannabinoid receptors: CNS localization of the CB(1) cannabinoid receptor. Curr Top Behav Neurosci 1:65-86.
69. Kedzior KK, Laeber LT (2014) A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population--a meta-analysis of 31 studies. BMC Psychiatry 14:136.
70. Krebs MO, Morvan Y, Jay T, Gaillard R, Kebir O (2014) Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students. Mol Psychiatry 19:402-403.
71. Lachman HM, Morrow B, Shprintzen R, Veit S, Parsia SS, Faedda G, Goldberg R, Kucherlapati R, Papolos DF (1996) Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome. Am J Med Genet 67:468-472.
72. Laviolette SR, Grace AA (2006) The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction. Cell Mol Life Sci 63:1597-1613.
73. Lee TT, Hill MN, Hillard CJ, Gorzalka BB (2013) Temporal changes in N-acylethanolamine content and metabolism throughout the peri-adolescent period. Synapse 67:4-10.
74. Leroy S, Griffon N, Bourdel MC, Olie JP, Poirier MF, Krebs MO (2001) Schizophrenia and the cannabinoid receptor type 1 (CB1): association study using a single-base polymorphism in coding exon 1. Am J Med Genet 105:749-752.
75. Leweke FM, Giuffrida A, Koethe D, Schreiber D, Nolden BM, Kranaster L, Neatby MA, Schneider M, Gerth CW, Hellmich M, Klosterkotter J, Piomelli D (2007) Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr Res 94:29-36.
76. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D (1999) Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10:1665-1669.
77. Long LE, Chesworth R, Arnold JC, Karl T (2010) A follow-up study: acute behavioural effects of Delta(9)-THC in female heterozygous neuregulin 1 transmembrane domain mutant mice. Psychopharmacology (Berl) 211:277-289.
78. Long LE, Chesworth R, Huang XF, McGregor IS, Arnold JC, Karl T (2013) Transmembrane domain Nrg1 mutant mice show altered susceptibility to the neurobehavioural actions of repeated THC exposure in adolescence. Int J Neuropsychopharmacol 16:163-175.
79. Lopez-Larson MP, Bogorodzki P, Rogowska J, McGlade E, King JB, Terry J, Yurgelun-Todd D (2011) Altered prefrontal and insular cortical thickness in adolescent marijuana users. Behav Brain Res 220:164-172.
80. Lopez-Larson MP, Rogowska J, Bogorodzki P, Bueler CE, McGlade EC, Yurgelun-Todd DA (2012) Cortico-cerebellar abnormalities in adolescents with heavy marijuana use. Psychiatry Res 202:224-232.
81. Llorente-Berzal A, Puighermanal E, Burokas A, Ozaita A, Maldonado R, Marco EM, Viveros MP (2013) Sex-dependent psychoneuroendocrine effects of THC and MDMA in an animal model of adolescent drug consumption. PLoS One 8:e78386.
82. Lynskey MT, Glowinski AL, Todorov AA, Bucholz KK, Madden PA, Nelson EC, Statham DJ, Martin NG, Heath AC (2004) Major depressive disorder, suicidal ideation, and suicide attempt in twins discordant for cannabis dependence and early-onset cannabis use. Arch Gen Psychiatry 61:1026-1032.
83. Malone DT, Taylor DA (2006) The effect of Delta9-tetrahydrocannabinol on sensorimotor gating in socially isolated rats. Behav Brain Res 166:101-109.
84. Manzoni OJ, Bockaert J (2001) Cannabinoids inhibit GABAergic synaptic transmission in mice nucleus accumbens. Eur J Pharmacol 412:R3-R5.
85. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, Azad SC, Cascio MG, Gutierrez SO, van der Stelt M, Lopez-Rodriguez ML, Casanova E, Schutz G, Zieglgansberger W, Di M, V, Behl C, Lutz B (2003) CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302:84-88.
86. Marsicano G, Lutz B (1999) Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 11:4213-4225.
87. Mato S, Del OE, Pazos A (2003) Ontogenetic development of cannabinoid receptor expression and signal transduction functionality in the human brain. Eur J Neurosci 17:1747-1754.
88. Medina KL, Hanson KL, Schweinsburg AD, Cohen-Zion M, Nagel BJ, Tapert SF (2007a) Neuropsychological functioning in adolescent marijuana users: subtle deficits detectable after a month of abstinence. J Int Neuropsychol Soc 13:807-820.
89. Medina KL, McQueeny T, Nagel BJ, Hanson KL, Yang TT, Tapert SF (2009) Prefrontal cortex morphometry in abstinent adolescent marijuana users: subtle gender effects. Addict Biol 14:457-468.
90. Medina KL, Nagel BJ, Park A, McQueeny T, Tapert SF (2007b) Depressive symptoms in adolescents: associations with white matter volume and marijuana use. J Child Psychol Psychiatry 48:592-600.
91. Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, McDonald K, Ward A, Poulton R, Moffitt TE (2012) Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A 109:E2657-E2664.
92. Molina-Holgado E, Vela JM, Arevalo-Martin A, Almazan G, Molina-Holgado F, Borrell J, Guaza C (2002) Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3kinase/Akt signaling. J Neurosci 22:9742-9753.
93. Morozov YM, Freund TF (2003) Post-natal development of type 1 cannabinoid receptor immunoreactivity in the rat hippocampus. Eur J Neurosci 18:1213-1222.
94. Mueser KT, Bellack AS, Blanchard JJ (1992) Comorbidity of schizophrenia and substance abuse: implications for treatment. J Consult Clin Psychol 60:845-856.
95. Mulder J, Aguado T, Keimpema E, Barabas K, Ballester Rosado CJ, Nguyen L, Monory K, Marsicano G, Di M, V, Hurd YL, Guillemot F, Mackie K, Lutz B, Guzman M, Lu HC, Galve-Roperh I, Harkany T (2008) Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning. Proc Natl Acad Sci U S A 105:8760-8765.
96. Newell KA, Deng C, Huang XF (2006) Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp Brain Res 172:556-560.
97. O'Shea M, McGregor IS, Mallet PE (2006) Repeated cannabinoid exposure during perinatal, adolescent or early adult ages produces similar longlasting deficits in object recognition and reduced social interaction in rats. J Psychopharmacol 20:611-621.
98. O'Tuathaigh CM, Clarke G, Walsh J, Desbonnet L, Petit E, O'Leary C, Tighe O, Clarke N, Karayiorgou M, Gogos JA, Dinan TG, Cryan JF, Waddington JL (2012) Genetic vs. pharmacological inactivation of COMT influences cannabinoid-induced expression of schizophrenia-related phenotypes. Int J Neuropsychopharmacol 15:1331-1342.
99. O'Tuathaigh CM, Hryniewiecka M, Behan A, Tighe O, Coughlan C, Desbonnet L, Cannon M, Karayiorgou M, Gogos JA, Cotter DR, Waddington JL (2010) Chronic adolescent exposure to Delta-9-tetrahydrocannabinol in COMT mutant mice: impact on psychosis-related and other phenotypes. Neuropsychopharmacology 35:2262-2273.
100. Oades RD, Klimke A, Henning U, Rao ML (2002) Relations of clinical features, subgroups and medication to serum monoamines in schizophrenia. Hum Psychopharmacol 17:15-27.
101. Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W (2002) Cannabis use and mental health in young people: cohort study. BMJ 325:1195-1198.
102. Pedersen W (2008) Does cannabis use lead to depression and suicidal behaviours? A populationbased longitudinal study. Acta Psychiatr Scand 118:395-403.
103. Perry W, Minassian A, Feifel D, Braff DL (2001) Sensorimotor gating deficits in bipolar disorder patients with acute psychotic mania. Biol Psychiatry 50:418-424.
104. Pertwee RG (1999) Pharmacology of cannabinoid receptor ligands. Curr Med Chem 6:635-664.
105. Pope HG, Jr., Jacobs A, Mialet JP, Yurgelun-Todd D, Gruber S (1997) Evidence for a sex-specific residual effect of cannabis on visuospatial memory. Psychother Psychosom 66:179-184.
106. Puighermanal E, Busquets-Garcia A, Gomis-Gonzalez M, Marsicano G, Maldonado R, Ozaita A (2013) Dissociation of the pharmacological effects of THC by mTOR blockade. Neuropsychopharmacology 38:1334-1343.
107. Quinn HR, Matsumoto I, Callaghan PD, Long LE, Arnold JC, Gunasekaran N, Thompson MR, Dawson B, Mallet PE, Kashem MA, Matsuda-Matsumoto H, Iwazaki T, McGregor IS (2008) Adolescent rats find repeated Delta(9)-THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure. Neuropsychopharmacology 33:1113-1126.
108. Reilly D, Didcott P, Swift W, Hall W (1998) Long-term cannabis use: characteristics of users in an Australian rural area. Addiction 93:837-846.
109. Renard J, Krebs MO, Jay TM, Le PG (2013) Long-term cognitive impairments induced by chronic cannabinoid exposure during adolescence in rats: a strain comparison. Psychopharmacology (Berl) 225:781-790.
110. Rey JM, Sawyer MG, Raphael B, Patton GC, Lynskey M (2002) Mental health of teenagers who use cannabis. Results of an Australian survey. Br J Psychiatry 180:216-221.
111. Rodriguez de Fonseca F, Ramos JA, Bonnin A, Fernandez-Ruiz JJ (1993) Presence of cannabinoid binding sites in the brain from early postnatal ages. Neuroreport 4:135-138.
112. Romero J, Garcia-Palomero E, Berrendero F, Garcia-Gil L, Hernandez ML, Ramos JA, Fernandez-Ruiz JJ (1997) Atypical location of cannabinoid receptors in white matter areas during rat brain development. Synapse 26:317-323.
113. Rubino T, Realini N, Braida D, Alberio T, Capurro V, Vigano D, Guidali C, Sala M, Fasano M, Parolaro D (2009a) The depressive phenotype induced in adult female rats by adolescent exposure to THC is associated with cognitive impairment and altered neuroplasticity in the prefrontal cortex. Neurotox Res 15:291-302.
114. Rubino T, Realini N, Braida D, Guidi S, Capurro V, Vigano D, Guidali C, Pinter M, Sala M, Bartesaghi R, Parolaro D (2009b) Changes in hippocampal morphology and neuroplasticity induced by adolescent THC treatment are associated with cognitive impairment in adulthood. Hippocampus 19:763-772.
115. Rubino T, Vigano' D, Realini N, Guidali C, Braida D, Capurro V, Castiglioni C, Cherubino F, Romualdi P, Candeletti S, Sala M, Parolaro D (2008) Chronic delta 9-tetrahydrocannabinol during adolescence provokes sex-dependent changes in the emotional profile in adult rats: behavioral and biochemical correlates. Neuropsychopharmacology 33:2760-2771.
116. Sanchez-Blazquez P, Rodriguez-Munoz M, Garzon J (2014) The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia. Front Pharmacol 4:169.
117. Schneider M, Koch M (2003) Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 28:1760-1769.
118. Schneider M, Koch M (2007) The effect of chronic peripubertal cannabinoid treatment on deficient object recognition memory in rats after neonatal mPFC lesion. Eur Neuropsychopharmacol 17:180-186.
119. Schneider M, Schomig E, Leweke FM (2008) Acute and chronic cannabinoid treatment differentially affects recognition memory and social behavior in pubertal and adult rats. Addict Biol 13:345-357.
120. Schweinsburg AD, Brown SA, Tapert SF (2008) The influence of marijuana use on neurocognitive functioning in adolescents. Curr Drug Abuse Rev 1:99-111.
121. Schweinsburg AD, Schweinsburg BC, Medina KL, McQueeny T, Brown SA, Tapert SF (2010) The influence of recency of use on fMRI response during spatial working memory in adolescent marijuana users. J Psychoactive Drugs 42:401-412.
122. Solowij N, Jones KA, Rozman ME, Davis SM, Ciarrochi J, Heaven PC, Pesa N, Lubman DI, Yucel M (2012) Reflection impulsivity in adolescent cannabis users: a comparison with alcohol-using and non-substance-using adolescents. Psychopharmacology (Berl) 219:575-586.
123. Spear LP (2000) The adolescent brain and age-related behavioral manifestations. Neurosci Biobehav Rev 24:417-463.
124. Spencer JR, Darbyshire KM, Boucher AA, Kashem MA, Long LE, McGregor IS, Karl T, Arnold JC (2013) Novel molecular changes induced by Nrg1 hypomorphism and Nrg1-cannabinoid interaction in adolescence: a hippocampal proteomic study in mice. Front Cell Neurosci 7:15.
125. Stefanis NC, Delespaul P, Henquet C, Bakoula C, Stefanis CN, van OJ (2004) Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction 99:1333-1341.
126. Toga AW, Thompson PM, Sowell ER (2006) Mapping brain maturation. Trends Neurosci 29:148-159.
127. Tournier M, Sorbara F, Gindre C, Swendsen JD, Verdoux H (2003) Cannabis use and anxiety in daily life: a naturalistic investigation in a non-clinical population. Psychiatry Res 118:1-8.
128. Ujike H, Takaki M, Nakata K, Tanaka Y, Takeda T, Kodama M, Fujiwara Y, Sakai A, Kuroda S (2002) CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry 7:515-518.
129. Vaidya JG, Block RI, O'Leary DS, Ponto LB, Ghoneim MM, Bechara A (2012) Effects of chronic marijuana use on brain activity during monetary decision-making. Neuropsychopharmacology 37:618-629.
130. van Laar M, van Dorsselaer S, Monshouwer K, de Graaf R (2007) Does cannabis use predict the first incidence of mood and anxiety disorders in the adult population? Addiction 102:1251-1260
131. Verdoux H, Gindre C, Sorbara F, Tournier M, Swendsen JD (2003) Effects of cannabis and psychosis vulnerability in daily life: an experience sampling test study. Psychol Med 33:23-32.
132. Verdoux H, Tournier M, Cougnard A (2005) Impact of substance use on the onset and course of early psychosis. Schizophr Res 79:69-75.
133. Vigano D, Guidali C, Petrosino S, Realini N, Rubino T, Di M, V, Parolaro D (2009) Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia. Int J Neuropsychopharmacol 12:599-614.
134. Vinod KY, Hungund BL (2006) Role of the endocannabinoid system in depression and suicide. Trends Pharmacol Sci 27:539-545.
135. Wegener N, Koch M (2009) Behavioural disturbances and altered Fos protein expression in adult rats after chronic pubertal cannabinoid treatment. Brain Res 1253:81-91.
136. Wilson W, Mathew R, Turkington T, Hawk T, Coleman RE, Provenzale J (2000) Brain morphological changes and early marijuana use: a magnetic resonance and positron emission tomography study. J Addict Dis 19:1-22.
137. Yucel M, Solowij N, Respondek C, Whittle S, Fornito A, Pantelis C, Lubman DI (2008) Regional brain abnormalities associated with long-term heavy cannabis use. Arch Gen Psychiatry 65:694-701.
138. Zalesky A, Solowij N, Yucel M, Lubman DI, Takagi M, Harding IH, Lorenzetti V, Wang R, Searle K, Pantelis C, Seal M (2012) Effect of long-term cannabis use on axonal fibre connectivity. Brain 135:2245-2255.
139. Zamberletti E, Beggiato S, Steardo L, Jr., Prini P, Antonelli T, Ferraro L, Rubino T, Parolaro D (2014) Alterations of prefrontal cortex GABAergic transmission in the complex psychotic-like phenotype induced by adolescent delta-9-tetrahydrocannabinol exposure in rats. Neurobiol Dis 63:35-47.
140. Zavitsanou K, Garrick T, Huang XF (2004) Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28:355-360.